On a day when Merck reported strong sales for its launch of pulmonary arterial hypertension (PAH) treatment Winrevair (sotatercept) and stalwart cancer medicine Keytruda, the positive news was overshadowed by the suddenly flat sales of Gardasil.
Mere weeks after earning the FDA’s signoff on new drug Winrevair to treat PAH, Merck has kicked off an educational campaign around the rare disease.
Merck`s Biologic Winrevair (sotatercept) Receives Approval in U.S
US FDA approves Merck`s therapy for rare lung condition
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
NEW ORLEANS — Merck says sotatercept, Acceleron’s lead drug before the Big Pharma bought it for $11.5 billion, significantly improved scores on an exercise test in a pivotal trial for pulmonary arterial hypertension (PAH). Now, Merck is working toward an FDA filing for what it hopes can one day be a blockbuster drug.
For years, Merck & Co.’s most consequential clinical updates have often concerned Keytruda, the goldmine cancer treatment that’s redefined success for the company. But a new crop of cardiovascular readouts is continuing to build hope of fresh revenue streams to replace its oncology blockbuster.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept, Merck’s novel investigational activin signaling inhibitor biologic, in combination with stable background therapy for the treatment of adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1). Sotatercept significantly improved exercise capacity, increasing 6-minute walk distance (6MWD) by 40.8 meters (95% CI, 27.5-54.1; p<0.001) from baseline at week 24, the study’s primary endpoint.
Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline
Is Merck Moving Toward Another Blockbuster Drug Launch?